News & Articles

Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season

The AI-Rad Companion Brain MR and Prostate MR measures volumetric changes in brain, and segments prostate for targeted biopsy under MRI and ultrasound fusion imaging respectively

The Somatom scanner is equipped with a forward-looking camera and motorized wheels, allowing a single technologist to navigate the device through hospital hallways

Access Anti-SARS-CoV-2 is an easy-to-use 10-minute test on a portable device that provides highly accurate results on total Ig antibodies

The new kits are based on the technology of the PerkinElmer New Coronavirus Nucleic Acid Detection Kit

A Presidential award-winning laboratory has developed a new technology to address one of the most pressing challenges in nanomedicine

Watch this on-demand webinar to gain insight on how advanced flow cytometry and live-cell analysis can facilitate faster drug development

analytica gets a digital extension

Across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants

The kits aim to detect traces of SARS-CoV-2 virus on surfaces such as plastics, ceramics and stainless steel

Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.

It is the first and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology

The AccuPlex SARS-CoV-2 molecular controls kit is designed to measure day-to-day assay performance and contains positive materials

The collaboration is the first larger scale production run of Apta-1 as a non-GMP material, intended for use in GLP toxicology studies

The test outperforms other molecular tests with a low detection limit of 15 GEC/reaction (250 GEC/ml of sample) and a robust control system

The consortium aims to determine the dynamics, function and potential for therapeutic intervention of the RNA and protein structures of SARS-CoV-2

IgM assay has 95.51% positive predictive value even when disease incidence is only 3%

The new assays are designed to enable turnaround times for next-generation sequencing results of less than 24 hours